Estrella Immunopharma (ESLA) Competitors

Estrella Immunopharma logo
$0.33 -0.05 (-12.74%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$0.34 +0.01 (+1.63%)
As of 08:50 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ESLA vs. MOLN, ORGO, VYGR, FHTX, and OTLK

Should you buy Estrella Immunopharma stock or one of its competitors? Estrella Immunopharma's main competitors and comparable companies include Molecular Partners (MOLN), Organogenesis (ORGO), Voyager Therapeutics (VYGR), Foghorn Therapeutics (FHTX), and Oncobiologics (OTLK). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Estrella Immunopharma compare to Molecular Partners?

Molecular Partners (NASDAQ:MOLN) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Estrella Immunopharma's return on equity of 0.00% beat Molecular Partners' return on equity.

Company Net Margins Return on Equity Return on Assets
Molecular PartnersN/A -80.03% -62.56%
Estrella Immunopharma N/A N/A -436.30%

26.6% of Molecular Partners shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 5.9% of Molecular Partners shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Estrella Immunopharma has lower revenue, but higher earnings than Molecular Partners. Molecular Partners is trading at a lower price-to-earnings ratio than Estrella Immunopharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Molecular Partners$5.65M20.35-$74.41M-$1.68N/A
Estrella ImmunopharmaN/AN/A-$13.06M-$0.24N/A

Molecular Partners has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, indicating that its stock price is 12% less volatile than the broader market.

Molecular Partners currently has a consensus target price of $8.38, suggesting a potential upside of 194.17%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 2,312.55%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Molecular Partners.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Molecular Partners
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25
Estrella Immunopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

In the previous week, Estrella Immunopharma had 2 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Estrella Immunopharma and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.94 beat Estrella Immunopharma's score of 0.57 indicating that Molecular Partners is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Molecular Partners
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Estrella Immunopharma
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Molecular Partners beats Estrella Immunopharma on 8 of the 13 factors compared between the two stocks.

How does Estrella Immunopharma compare to Organogenesis?

Organogenesis (NASDAQ:ORGO) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability.

In the previous week, Estrella Immunopharma had 1 more articles in the media than Organogenesis. MarketBeat recorded 3 mentions for Estrella Immunopharma and 2 mentions for Organogenesis. Organogenesis' average media sentiment score of 1.05 beat Estrella Immunopharma's score of 0.57 indicating that Organogenesis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Organogenesis
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Estrella Immunopharma
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Estrella Immunopharma has a net margin of 0.00% compared to Organogenesis' net margin of -39.34%. Estrella Immunopharma's return on equity of 0.00% beat Organogenesis' return on equity.

Company Net Margins Return on Equity Return on Assets
Organogenesis-39.34% -55.28% -23.72%
Estrella Immunopharma N/A N/A -436.30%

Organogenesis has higher revenue and earnings than Estrella Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Organogenesis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Organogenesis$564.17M0.19$37.03M-$1.22N/A
Estrella ImmunopharmaN/AN/A-$13.06M-$0.24N/A

Organogenesis currently has a consensus price target of $4.33, suggesting a potential upside of 433.92%. Estrella Immunopharma has a consensus price target of $8.00, suggesting a potential upside of 2,312.55%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Organogenesis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Organogenesis
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Estrella Immunopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Organogenesis has a beta of 1.48, suggesting that its stock price is 48% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

49.6% of Organogenesis shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 18.8% of Organogenesis shares are held by insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Organogenesis and Estrella Immunopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Estrella Immunopharma compare to Voyager Therapeutics?

Estrella Immunopharma (NASDAQ:ESLA) and Voyager Therapeutics (NASDAQ:VYGR) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, media sentiment, institutional ownership, risk and dividends.

Estrella Immunopharma has a net margin of 0.00% compared to Voyager Therapeutics' net margin of -416.32%. Estrella Immunopharma's return on equity of 0.00% beat Voyager Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A -436.30%
Voyager Therapeutics -416.32%-63.42%-49.40%

Estrella Immunopharma has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market. Comparatively, Voyager Therapeutics has a beta of 1.2, meaning that its stock price is 20% more volatile than the broader market.

Estrella Immunopharma has higher earnings, but lower revenue than Voyager Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Voyager Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/A-$13.06M-$0.24N/A
Voyager Therapeutics$40.37M2.34-$119.72M-$1.73N/A

Estrella Immunopharma currently has a consensus price target of $8.00, suggesting a potential upside of 2,312.55%. Voyager Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 1,544.74%. Given Estrella Immunopharma's higher probable upside, equities research analysts clearly believe Estrella Immunopharma is more favorable than Voyager Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Estrella Immunopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Voyager Therapeutics
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 48.0% of Voyager Therapeutics shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 12.7% of Voyager Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Voyager Therapeutics had 6 more articles in the media than Estrella Immunopharma. MarketBeat recorded 9 mentions for Voyager Therapeutics and 3 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.57 beat Voyager Therapeutics' score of -0.03 indicating that Estrella Immunopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Estrella Immunopharma
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Voyager Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Voyager Therapeutics beats Estrella Immunopharma on 8 of the 14 factors compared between the two stocks.

How does Estrella Immunopharma compare to Foghorn Therapeutics?

Foghorn Therapeutics (NASDAQ:FHTX) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Foghorn Therapeutics has a beta of 3.22, meaning that its stock price is 222% more volatile than the broader market. Comparatively, Estrella Immunopharma has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

61.6% of Foghorn Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 9.0% of Foghorn Therapeutics shares are held by company insiders. Comparatively, 5.8% of Estrella Immunopharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Foghorn Therapeutics had 13 more articles in the media than Estrella Immunopharma. MarketBeat recorded 16 mentions for Foghorn Therapeutics and 3 mentions for Estrella Immunopharma. Estrella Immunopharma's average media sentiment score of 0.57 beat Foghorn Therapeutics' score of 0.37 indicating that Estrella Immunopharma is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Foghorn Therapeutics
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Estrella Immunopharma
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Foghorn Therapeutics has a net margin of 8.40% compared to Estrella Immunopharma's net margin of 0.00%. Estrella Immunopharma's return on equity of 0.00% beat Foghorn Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Foghorn Therapeutics8.40% -13.46% 4.63%
Estrella Immunopharma N/A N/A -436.30%

Foghorn Therapeutics currently has a consensus target price of $6.14, suggesting a potential upside of 235.68%. Estrella Immunopharma has a consensus target price of $8.00, suggesting a potential upside of 2,312.55%. Given Estrella Immunopharma's higher possible upside, analysts plainly believe Estrella Immunopharma is more favorable than Foghorn Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Foghorn Therapeutics
1 Sell rating(s)
6 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.27
Estrella Immunopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Estrella Immunopharma has lower revenue, but higher earnings than Foghorn Therapeutics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Foghorn Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foghorn Therapeutics$30.91M3.55-$74.28M$0.0726.14
Estrella ImmunopharmaN/AN/A-$13.06M-$0.24N/A

Summary

Foghorn Therapeutics beats Estrella Immunopharma on 10 of the 14 factors compared between the two stocks.

How does Estrella Immunopharma compare to Oncobiologics?

Estrella Immunopharma (NASDAQ:ESLA) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership.

In the previous week, Estrella Immunopharma had 2 more articles in the media than Oncobiologics. MarketBeat recorded 3 mentions for Estrella Immunopharma and 1 mentions for Oncobiologics. Oncobiologics' average media sentiment score of 0.91 beat Estrella Immunopharma's score of 0.57 indicating that Oncobiologics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Estrella Immunopharma
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Oncobiologics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Estrella Immunopharma has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.75, meaning that its share price is 25% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Estrella ImmunopharmaN/A N/A -436.30%
Oncobiologics N/A N/A -254.82%

0.4% of Estrella Immunopharma shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 5.8% of Estrella Immunopharma shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Estrella Immunopharma currently has a consensus price target of $8.00, indicating a potential upside of 2,312.55%. Oncobiologics has a consensus price target of $5.20, indicating a potential upside of 1,342.04%. Given Estrella Immunopharma's higher probable upside, research analysts clearly believe Estrella Immunopharma is more favorable than Oncobiologics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Estrella Immunopharma
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Oncobiologics
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Estrella Immunopharma has higher earnings, but lower revenue than Oncobiologics. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Estrella ImmunopharmaN/AN/A-$13.06M-$0.24N/A
Oncobiologics$1.35M65.03-$62.42M-$0.77N/A

Summary

Estrella Immunopharma and Oncobiologics tied by winning 6 of the 12 factors compared between the two stocks.

Get Estrella Immunopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ESLA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ESLA vs. The Competition

MetricEstrella ImmunopharmaBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$16.53M$4.06B$7.83B$11.74B
Dividend YieldN/A3.63%2.47%4.47%
P/E RatioN/A26.7033.9728.44
Price / SalesN/A15.788.495.70
Price / CashN/A22.9521.0121.90
Price / Book-1.234.184.453.72
Net Income-$13.06M-$24.15M$3.52B$393.10M
7 Day Performance-58.23%-7.79%-5.94%-5.77%
1 Month Performance-22.88%-5.95%-4.58%-7.14%
1 Year Performance-81.78%-8.08%-1.95%-7.47%

Estrella Immunopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ESLA
Estrella Immunopharma
1.8585 of 5 stars
$0.33
-12.7%
$8.00
+2,312.5%
-82.2%$16.53MN/AN/A3
MOLN
Molecular Partners
3.2349 of 5 stars
$3.06
-1.1%
$8.38
+174.1%
-33.2%$124.76M$5.65MN/A134
ORGO
Organogenesis
1.6811 of 5 stars
$1.05
+12.3%
$4.33
+312.7%
-86.5%$121.39M$564.17MN/A854
VYGR
Voyager Therapeutics
2.3747 of 5 stars
$1.76
-3.6%
$25.00
+1,320.5%
-63.0%$113.57M$40.37MN/A141
FHTX
Foghorn Therapeutics
3.7902 of 5 stars
$2.09
+10.0%
$6.14
+193.9%
-62.0%$112.83M$112.13M29.86106

Related Companies and Tools


This page (NASDAQ:ESLA) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners